Scholars@Duke
Kristen Said

Kristen Said

Assistant Professor in Family Medicine and Community Health
Family Medicine and Community Health, Occupational & Environmental
kristen.said@duke.edu
Employee Health 04268 Hospital, Box 3148 DUMC, Durham, NC 27710
Office hours

Selected Publications

Paid sick leave among US private sector employees.

Journal Article Am J Ind Med · September 2022 BACKGROUND: Inequities in US employees' access to paid sick leave are known, but it is not clear whether they are increasing or decreasing over time. More than two dozen state and local paid sick leave laws were recently enacted, many with the stated goal ... Full text Link to item Cite

Partnerships to Care for Our Patients and Communities During COVID-19.

Journal Article J Am Board Fam Med · 2021 The Coronavirus disease 2019 (COVID-19) pandemic forced not only rapid changes in how clinical care and educational programs are delivered but also challenged academic medical centers (AMCs) like never before. The pandemic made clear the need to have coord ... Full text Open Access Link to item Cite

Tolevamer, an orally administered, toxin-binding polymer for Clostridium difficile-associated diarrhea.

Journal Article Curr Opin Investig Drugs · August 2008 Genzyme Corp is developing tolevamer, an anionic toxin-binding polymer that binds and neutralizes the Clostridium difficile A and B toxins, for the potential treatment of C difficile-associated diarrhea (CDAD). Two phase III clinical trials of tolevamer in ... Link to item Cite

Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.

Journal Article Curr Opin Investig Drugs · April 2008 Savient Pharmaceuticals Inc (formerly Bio-Technology General Corp), under license from Duke University, is developing pegloticase, PEG conjugates of uricase (urate oxidase), for the potential treatment of gout. The in-life portion of the phase III trials h ... Link to item Cite

VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer.

Journal Article Curr Opin Mol Ther · April 2008 Viventia Biotech Inc, under license from the University of Zurich, is developing VB4-845, comprising a Pseudomonas exotoxin fused to an anti-epithelial cell adhesion molecule single-chain antibody fragment, for the potential treatment of head and neck canc ... Link to item Cite